Should Tumor Infiltrating Lymphocytes, Androgen Receptor, and FOXA1 Expression Predict the Clinical Outcome in Triple Negative Breast Cancer Patients?
AR
FOXA1
TILs
TNBC
prognosis
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
18 Sep 2019
18 Sep 2019
Historique:
received:
07
08
2019
revised:
28
08
2019
accepted:
09
09
2019
entrez:
22
9
2019
pubmed:
22
9
2019
medline:
22
9
2019
Statut:
epublish
Résumé
Tumor-infiltrating lymphocytes (TILs) are a valuable indicator of the immune microenvironment that plays the central role in new anticancer drugs. TILs have a strong prognostic role in triple negative breast cancer (TNBC). Little is known about the interaction with the androgen receptor (AR) and forkhead box A1 (FOXA1). We analyzed the relationships between TIL levels, AR, and FOXA1 expression and their clinical significance in TNBC patients. Further, we investigated their interaction with other biomarkers like programmed cell death ligand-1 (PD-L1), breast cancer type 1 susceptibility protein (BRCA1), poly (ADP-Ribose) polymerase 1 (PARP1), and Na+/H+ exchanger regulatory factor 1 (NHERF1). The expression of the proteins was evaluated by immunohistochemistry in 124 TNBC samples. TILs were performed adhering to International TILs Working Group 2014 criteria. Cox proportional hazards models were also used to identify risk factors associated with poor prognosis. Multivariate analysis identified TILs as independent prognostic factor of disease free survival (DFS;
Identifiants
pubmed: 31540486
pii: cancers11091393
doi: 10.3390/cancers11091393
pmc: PMC6769726
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Mol Endocrinol. 2004 Dec;18(12):2895-907
pubmed: 15358834
Ann Oncol. 2015 Feb;26(2):259-71
pubmed: 25214542
J Clin Pathol. 2008 Mar;61(3):327-32
pubmed: 18037662
Oncotarget. 2017 Aug 12;8(48):83986-83994
pubmed: 29137398
Mol Oncol. 2015 Apr;9(4):877-88
pubmed: 25616998
Oncotarget. 2016 Oct 11;7(41):67142-67149
pubmed: 27613839
Cancer Sci. 2013 May;104(5):639-46
pubmed: 23373898
Lancet. 2012 Feb 4;379(9814):432-44
pubmed: 22152853
Oncologist. 2016 Sep;21(9):1050-62
pubmed: 27401886
JAMA Oncol. 2016 Oct 1;2(10):1354-1360
pubmed: 27355489
J Clin Oncol. 2010 Jan 1;28(1):105-13
pubmed: 19917869
Cancers (Basel). 2017 Jan 06;9(1):null
pubmed: 28067809
J Mol Cell Biol. 2011 Feb;3(1):59-65
pubmed: 21278453
J Natl Cancer Inst. 2014 Jan;106(1):djt319
pubmed: 24273215
Oncol Lett. 2018 Jun;15(6):10008-10016
pubmed: 29844843
Proc Natl Acad Sci U S A. 2005 Aug 16;102(33):11651-6
pubmed: 16087863
Br J Cancer. 2018 Jul;119(1):76-79
pubmed: 29880907
Transl Oncol. 2018 Apr;11(2):311-329
pubmed: 29413765
J Exp Clin Cancer Res. 2018 May 2;37(1):96
pubmed: 29716631
Ann Surg Oncol. 2014 Feb;21(2):361-7
pubmed: 24046116
Breast Cancer Res Treat. 2016 Jul;158(2):323-31
pubmed: 27372069
Breast Cancer Res Treat. 2010 May;121(1):1-11
pubmed: 19533338
Ann Surg Oncol. 2015 Jan;22(1):82-9
pubmed: 25145503
Cancer Biol Med. 2015 Jun;12(2):106-16
pubmed: 26175926
Nat Genet. 2011 Jan;43(1):27-33
pubmed: 21151129
J Breast Cancer. 2015 Jun;18(2):134-42
pubmed: 26155289
Int J Cancer. 2019 May 15;:null
pubmed: 31090219
PLoS One. 2016 Apr 13;11(4):e0152500
pubmed: 27073890
Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4429-34
pubmed: 17671126
Breast Cancer Res Treat. 2019 Nov;178(2):283-294
pubmed: 31402409
Oncotarget. 2017 Feb 28;8(9):15584-15592
pubmed: 28107186
Cancer Cell. 2011 Jul 12;20(1):119-31
pubmed: 21741601
Breast. 2016 Jun;27:35-43
pubmed: 27212698
Cell Death Dis. 2013 Nov 07;4:e904
pubmed: 24201803
Tumour Biol. 2016 May;37(5):6143-53
pubmed: 26614429
Oncotarget. 2016 Jul 19;7(29):46482-46491
pubmed: 27374089
Oncotarget. 2017 Jan 31;8(5):7753-7765
pubmed: 27999191
Cell. 2005 Jul 15;122(1):33-43
pubmed: 16009131
Oncotarget. 2017 Jul 22;8(39):65730-65742
pubmed: 29029467
Cancer Res. 2017 Jul 1;77(13):3455-3466
pubmed: 28512248
Clin Transl Oncol. 2016 May;18(5):497-506
pubmed: 26459255
Ann Oncol. 2014 Mar;25(3):611-8
pubmed: 24401929
J Clin Oncol. 2007 Jan 1;25(1):118-45
pubmed: 17159189
Clin Cancer Res. 2001 Jun;7(6):1669-75
pubmed: 11410505
Breast Cancer Res Treat. 2012 Feb;131(3):881-90
pubmed: 21503684
Cancer Sci. 2012 Apr;103(4):626-31
pubmed: 22212856
J Biol Chem. 1991 Jan 5;266(1):510-8
pubmed: 1985913
J Natl Cancer Inst. 2014 Apr 28;106(5):null
pubmed: 24777111
Expert Opin Biol Ther. 2017 Jun;17(6):709-721
pubmed: 28375039
Cancers (Basel). 2019 Jul 22;11(7):null
pubmed: 31336689
Oncogene. 2015 Sep 24;34(39):5012-24
pubmed: 25531315
Cancer Treat Rev. 2018 Feb;63:122-134
pubmed: 29287242
Breast Cancer Res. 2018 Jun 22;20(1):62
pubmed: 29929548
EMBO J. 2011 Jun 24;30(15):3019-27
pubmed: 21701558
Cancers (Basel). 2019 Jul 25;11(8):null
pubmed: 31349612